邮件订阅 RSS 中文 | English
高级检索
沈超琴，刘韬韬. m6A-脂肪酸代谢相关lncRNA对结肠癌预后及免疫疗效的预测价值[J]. 中国临床医学, 2024, 31(1): 68-77. DOI: 10.12025/j.issn.1008-6358.2024.20231786
引用本文: 沈超琴，刘韬韬. m6A-脂肪酸代谢相关lncRNA对结肠癌预后及免疫疗效的预测价值[J]. 中国临床医学, 2024, 31(1): 68-77. DOI: 10.12025/j.issn.1008-6358.2024.20231786
shu
SHEN C Q, LIU T T. Predictive values of m6A-fatty-acid-metabolism-related lncRNA in prognosis and immune efficiency of colon cancer[J]. Chin J Clin Med, 2024, 31(1): 68-77. DOI: 10.12025/j.issn.1008-6358.2024.20231786
Citation: SHEN C Q, LIU T T. Predictive values of m6A-fatty-acid-metabolism-related lncRNA in prognosis and immune efficiency of colon cancer[J]. Chin J Clin Med, 2024, 31(1): 68-77. DOI: 10.12025/j.issn.1008-6358.2024.20231786
shu

m6A-脂肪酸代谢相关lncRNA对结肠癌预后及免疫疗效的预测价值

Predictive values of m6A-fatty-acid-metabolism-related lncRNA in prognosis and immune efficiency of colon cancer

    摘要
  • 摘要:
    目的 探讨结肠癌中m6A-脂肪酸代谢相关lncRNA, 并分析其与患者预后及肿瘤免疫微环境的相关性, 为结肠癌患者诊治提供新的分子靶点。
    方法 从TCGA数据库中获取结肠癌患者的转录组数据及临床信息。通过Pearson相关分析筛选出m6A-脂肪酸代谢相关lncRNA。采用单因素、LASSO及多因素Cox回归分析构建基于lncRNA表达的风险模型; 通过Kaplan-Meier生存曲线、ROC曲线及列线图验证风险模型的准确性。比较高风险组及低风险组结肠癌患者免疫细胞浸润情况。
    结果 从TCGA数据库中鉴定出670个m6A相关lncRNA及1 011个脂肪酸代谢相关lncRNA, 其中39个交叉的lncRNA具有预后意义。通过LASSO及多因素回归构建了包含5个m6A-脂肪酸代谢相关lncRNA的风险模型, 风险评分较高者预后较差。多因素Cox回归分析表明风险评分是影响患者预后的独立相关因素(HR=11.8, 95%CI 3.6~38.7)。ROC曲线显示其预测患者1年、3年、5年生存率的曲线下面积分别为0.758 (95%CI 0.611~0.905)、0.793 (95%CI 0.708~0.877)和0.815 (95%CI 0.722~0.907)。相较于高风险组, 低风险组肿瘤有更多的M1型巨噬细胞浸润(P < 0.05), 免疫检查点基因(CD44、TNFRSF9、CD40LG、CD48、CD244、IDO1、HAVCR2、CD27、ICOS、LAIR1、TMIGD2、CD28、TIGIT)表达增高(P < 0.05)。
    结论 该m6A-脂肪酸代谢相关lncRNA风险模型可用于预测结肠癌患者预后及免疫疗效。

     

    Abstract:
    Objective To explore the m6A-fatty-acid-metabolism-related lncRNAs in colon cancer, and to analyze their correlation with colon cancer prognosis and tumor immune microenvironment, thus providing new molecular targets for diagnosis and treatment of colon cancer patients.
    Methods Transcriptome data and relevant clinical information of colon cancer patients were downloaded from TCGA database. m6A-fatty-acid-metabolism-related lncRNAs were identified through Pearson correlation analysis. The risk model based on lncRNA expression was established using univariate Cox regression analysis, LASSO regression analysis, and multivariate Cox regression analysis. The validity of the prognostic risk model was verified using Kaplan-Meier survival analysis, ROC curve, and nomogram. The immune cell infiltration was compared between high-risk and low-risk groups.
    Results 670 m6A-related lncRNAs and 1 011 fatty-acid-metabolism-related lncRNAs were identified from TCGA, and 39 lncRNAs of their intersection had prognostic significance. A risk model containing 5 lncRNAs related to m6A modification and fatty acid metabolism was established using LASSO and multivariate Cox regression analysis. Colon cancer patients with higher risk scores were more likely to have a worse prognosis than those with lower risk scores. Multivariate Cox regression analysis indicated that the risk score was an independent prognostic factor for colon cancer (HR=11.8, 95%CI 3.6-38.7). ROC analysis manifested that the area under curve (AUC) of the model predicting survival rate at 1, 3 and 5 years were 0.758 (95%CI 0.611-0.905), 0.793 (95%CI 0.708-0.877) and 0.815 (95%CI 0.722-0.907). Compared with the high-risk group, the low-risk group had increased M1 macrophages (P < 0.05) and higher expression of immune checkpoints (CD44, TNFRSF9, CD40LG, CD48, CD244, IDO1, HAVCR2, CD27, ICOS, LAIR1, TMIGD2, CD28 and TIGIT; P < 0.05).
    Conclusions This m6A-fatty-acid-metabolism-related lncRNA risk model could be used to predict prognosis and immunotherapy response of colon cancer patients.

     

    • HTML全文
    • 参考文献(44)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回